COVID-19 Collection thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
The vaccine effectiveness of two doses of Moderna mRNA-1273 is 87.4% against COVID-19 infection and 95.8 and 97.9% against COVID-19 hospitalization and hospital death, respectively.
Share this article
Share this article
PASADENA, Calif., March 10, 2021 /PRNewswire/ A Kaiser Permanente study showed that one type of pneumonia vaccine, the PCV13 vaccine, may affect the course of COVID-19 for some older adult patients. The study was published in The Journal of Infectious Diseases. Kaiser Permanente members who received the PCV13 vaccine appeared to be diagnosed with COVID-19 less often, and when they were, they seemed to have less severe outcomes, overall, said the senior author, Sara Y. Tartof, PhD, MPH, a scientist with the Kaiser Permanente Southern California Department of Research & Evaluation. One of the most interesting aspects of our findings was that the patients who received PCV13 received some protection against COVID-19, while those who received PPSV23, another pneumococcal vaccine, did not.